(ETNB), highlighted by the initiation of two global pivotal trials targeting advanced MASH patients, as well as completion of enrollment in our Phase 3 ENTRUST trial in SHTG,” stated Rohan Palekar, ...
ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic ...
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the ...
Emerging evidence suggests that fibroblast growth factor 21 (FGF21) could play a future part in the treatment of metabolic ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Californian biotech 89bio has joined the small group of drugmakers with proof-of-concept clinical results in the fatty liver disease non-alcoholic steatohepatitis (NASH), encouraging enough for it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results